Table.
Laboratory Findings at 28 Months after the End of Chemotherapy.
| Hematology | Serology | ||||
| WBC | 6,700 | /μL | CRP | 0.49 | mg/dL |
| Neutro. | 50.0 | % | IgG | 1,972 | mg/dL |
| Lympho. | 33.0 | % | IgA | 256 | mg/dL |
| RBC | 505×104 | /μL | IgM | 30 | mg/dL |
| Hb | 14.2 | g/dL | |||
| Ht | 42.3 | % | Tumor marker | ||
| Plt | 18.3×104 | /μL | sIL-2R | 1,381 | U/mL |
| Biochemistry | Coagulation | ||||
| TP | 8.0 | g/dL | PT% | 96.0 | % |
| Alb | 4.1 | g/dL | PT-INR | 1.02 | |
| T-bil | 0.4 | mg/dL | APTT | 39.6 | sec |
| AST | 21 | IU/L | Fibrinogen | 501 | mg/dL |
| ALT | 14 | IU/L | |||
| LDH | 105 | IU/L | HBV markers | ||
| ALP | 445 | IU/L | HBsAg | 19.5 | COI |
| GGT | 42 | IU/L | Anti-HBs | (-) | mIU/mL |
| T-cho | 188 | mg/dL | HBeAg | 9.6 | COI |
| BUN | 20 | mg/dL | Anti-HBe | 51.7 | % |
| Cre | 1.08 | mg/dL | HBV-DNA | 4.4 | log copies/mL |
| UA | 7.0 | mg/dL | HBcrAg | 5.6 | log U/mL |
| FPG | 106 | mg/dL | Genotype | indeterminate | |
| PC/CP type | wild/wild | ||||
WBC: white blood cell, RBC: red blood cell, Hb: hemoglobin, Ht: hematocrit, Plt: platelet, TP: total protein, Alb: albumin, T-bil: total bilirubin, AST: aspartate aminotransferase, ALT: alanine aminotransferase, LDH: lactate dehydrogenase, ALP: alkaline phosphatase, GGT: gamma glutamyl transpeptidase, T-cho: total cholesterol, TG: triglyceride, Amy: amylase, BUN: blood urea nitrogen, Cre: creatinine, FPG: fasting plasma glucose, CRP: C-reactive protein, sIL-2R: soluble interleukin-2 receptor, PT: prothrombin time, APTT activated partial thromboplastin time, HBsAg: hepatitis B surface antigen, Anti-HBs: hepatitis B surface antibody, HBeAg: hepatitis B e antigen, Anti-HBe: hepatitis B e antibody, HBcrAg: hepatitis B core related antigen, PC: precore, CP: core promotor